Lv3
377 积分 2025-10-27 加入
The evolving treatment paradigm of chimeric antigen receptor T-cell therapy in lymphoma
1天前
已完结
Advances in chimeric antigen receptor-T therapies to target tumor resistance in B-cell malignancies
1天前
待确认
T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities
1天前
已完结
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
1天前
已完结
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy – A Report from the CIBMTR
1天前
已完结
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy – A report from the CIBMTR
1天前
已完结
Accelerating and optimising CAR T-cell manufacture to deliver better patient products
1天前
已完结
Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial
1天前
求助中
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma
2天前
已完结
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study
20天前
已完结
皖公网安备34019202002308
